Biocon’s Growth Rides On FDA Site Inspection Outcomes After Muted Q2
Biosimilars Was The Only Business Segment To Report Increased YoY Sales
After under-delivering on already muted expectations, Biocon's optimistic future was overshadowed by pending FDA inspection outcomes on two of its facilities.
